The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
Open accessAbstract
A plethora of myeloma growth factors (MGFs) has been identified, but their relative importance and cooperation have not been determined. We investigated 5 MGFs (interleukin-6 [IL-6], insulin-like growth factor type 1 [IGF-1], hepatocyte growth factor [HGF], HB–epidermal growth factor [HB-EGF], and a proliferation-inducing ligand [APRIL]) in serum-free cultures of human myeloma cell lines (HMCLs). In CD45− HMCLs, an autocrine IGF-1 loop promoted autonomous survival whereas CD45+ HMCLs could not survive without addition of MGFs, mainly IGF-1 and IL-6. IGF-1 was the major one: its activity was abrogated by an IGF-1R inhibitor only, whereas IL-6, HGF, or HB-EGF activity was inhibited by both IGF-1R– and receptor-specific inhibition. APRIL activity was inhibited by its specific inhibitor only. Of the investigated MGFs and their receptors, only expressions of IGF-1R and IL-6R in multiple myeloma cells (MMCs) of patients delineate a group with adverse prognosis. This is mainly explained by a strong association of IGF-1R and IL-6R expression and t(4;14) translocation, but IGF-1R expression without t(4;14) can also have a poor prognosis. Thus, IGF-1–targeted therapy, eventually in combination with anti–IL-6 therapy, could be promising in a subset of patients with MMCs expressing IGF-1R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Self-citationInterleukin-21 is a growth and survival factor for human myeloma cells
Brenne, A.-T., Baade Ro, T., Waage, A., Sundan, A., Borset, M., & Hjorth-Hansen, H. (2002) · Blood · doi:10.1182/blood.v99.10.3756 · Cited by 168 · cited 2×
“3-100 (21-124) 16-98 (8-107) 34-100 (19-283) 97 (29) 25 (12) 97 (84) Range Median 1-2 (4-17) 0.”
Mahtouk, K., Cremer, F. W., Rème, T., Jourdan, M., Baudard, M., Moreaux, J., Requirand, G., Fiol, G., De Vos, J., Moos, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209699 · Cited by 105
Self-citation
Cited by
Wang, J., Hendrix, A., Hernot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., Lahoutte, T., De Wever, O., Vanderkerken, K., & Menu, E. (2014) · Blood · doi:10.1182/blood-2014-03-562439 · Cited by 441
Interleukin-6 as a Therapeutic Target
Rossi, J.-F., Lu, Z.-Y., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 366
Self-citationCho, S.-F., Anderson, K. C., & Tai, Y.-T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01821 · Cited by 294
Mollinedo, F., & Gajate, C. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr119000439 · Cited by 279
Lalancette-Hébert, M., Swarup, V., Beaulieu, J. M., Bohacek, I., Abdelhamid, E., Weng, Y. C., Sato, S., & Kriz, J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1498-12.2012 · Cited by 251
Metadata
- Authors
- Sprynski, A. C., Hose, D., Caillot, L., Réme, T., Shaughnessy, J. D., Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., Meißner, T., Jauch, A., Mahtouk, K., Kassambara, A., Bertsch, U., Rossi, J. F., Goldschmidt, H., & Klein, B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-05-07
- Volume
- 113
- Issue
- 19
- Pages
- 4614-4626
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2051019115
- Cited by
- 173
- References
- 4
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. https://app.cochat.ai/papers/10.1182/blood-2008-07-170464
- The paper
- Sprynski, A. C., Hose, D., Caillot, L., Réme, T., Shaughnessy, J. D., Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., Meißner, T., Jauch, A., Mahtouk, K., Kassambara, A., Bertsch, U., Rossi, J. F., Goldschmidt, H., & Klein, B. (2009). The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. https://doi.org/10.1182/blood-2008-07-170464
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.